Physician profile
Odelia Cooper
NPI 1598977407
$4,132.74
in general payments reported to CMS, 2019-2025
5 companies · $3,570 in 2025
The $3,570 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $0.35 · 2022: $26.76 · 2025: $3,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,570.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $3,570.00 | 2025 | |
| Novo Nordisk INC | $326.72 | 2019 | |
| Pfizer INC. | $192.69 | 2019 | |
| Insulet Corporation | $42.98 | 2019-2022 | |
| Travere Therapeutics, INC. | $0.35 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Odelia Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.